Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.

Thromboinflammatory response in SARS-CoV-2 sepsis / Maiese, A.; Passaro, G.; de Matteis, A.; Fazio, Valentina; La Russa, Raffaele; Paolo, M. D.. - In: THE MEDICO-LEGAL JOURNAL. - ISSN 0025-8172. - (2020), pp. 1-3. [10.1177/0025817220926915]

Thromboinflammatory response in SARS-CoV-2 sepsis

Maiese A.;de Matteis A.;valentina Fazio.;la russa Raffaele;
2020

Abstract

Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.
File allegati a questo prodotto
File Dimensione Formato  
Maiese_Thromboinflammatory_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 259.31 kB
Formato Adobe PDF
259.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1470417
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 20
  • ???jsp.display-item.citation.isi??? ND
social impact